Table 3.
Pharmacological experimental drugs for COVID-19 among treated outpatients.
| Overall | Male | Female | p-Value | |
|---|---|---|---|---|
| n: 201 | n: 115 | n: 86 | ||
| Azithromycin alone, (%) | 86 (42.78%) | 47 (40.86%) | 39 (45.34%) | 0.52 |
| Hydroxychloroquine alone, n (%) | 4 (1.99%) | 3 (2.60%) | 1 (1.16%) | 0.47 |
| Cortisone alone, n (%) | 5 (2.48%) | 2 (1.74%) | 3 (3.48%) | 0.43 |
| Azithromycin + Hydroxychloroquine, n (%) | 22 (10.94%) | 13 (11.30%) | 9 (10.46%) | 0.85 |
| Azithromycin + Cortisone, n (%) | 21 (10.44%) | 14 (12.17%) | 7 (8.14%) | 0.35 |
| Azithromycin + Hydroxychloroquine + Cortisone, n (%) | 13 (6.46%) | 7 (6.08%) | 6 (6.97%) | 0.80 |
| Low Molecular Weight Heparin, n (%) | 50 (24.87%) | 29 (25.21%) | 21 (24.41%) | 0.89 |